Study on Seepage Characteristics of Grouting Slurry for Water-Absorbing Mudstone with Rough Fissure.

Based on the computed tomography scanning, which abbreviation is CT scanning, and fractal theory, geometric parameters of mudstone fissures are obtained. The physical model of a single fissured channel is obtained in combination with Barton standard curves and 3D printing technology, and similar materials of mudstone are developed based on the water absorption of natural mudstone to prepare single fissured water-absorbing grouting test blocks with different roughness levels for the grouting simulation testing. By analyzing the viscosity change characteristics of grouting slurry before and after grouting, the seepage characteristics of the grouting slurry in the rough fissures of the water-absorbing mudstone are revealed. The results show that when the roughness is small, the grouting slurry will have an obvious water loss effect after passing through mudstone fissures. However, with the flow of the slurry, the water loss effect of the subsequent grouting slurry will be weakened. For fissures with high roughness, the water absorption properties of the rough surfaces and the walls of the mudstone fissures work together, leading to the sedimentation and blockage of the fissure channels, thereby hindering the flow of slurry.

[Lamivudine, interferon-alpha and oxymatrine treatment for the surviving hepatic failure patients with hepatitis B].

OBJECTIVE: To investigate the effect of lamivudine, interferon alpha and oxymatrine treatment for surviving hepatic failure patients with hepatitis B. METHODS: 200 hepatitis B patients, including 100 subacute or acute-on-chronic hepatic failure survivals (group A), and 100 chronic (group B, n=100) hepatic failure survivals, were enrolled in this study. Patients in group A received interferon alpha (n=35), lamivudine (n=33) , or combinational lamivudine and oxymatrine (n=32) therapy for six months; Patients in group B received lamivudine (n=49), or combinational lamivudine and oxymatrine (n=51) therapy for six months, respectively. After the treatment, all patients were followed-up for six months. RESULTS: At the end of follow-up, all patients in group A survived, while in group B three patients (6.1%) receiving lamivudine, and four (7.8%, P>0.05) receiving combinational therapy died; more than 90% of all survivals had their HBV DNA loss. The HBeAg/anti-HBe seroconversion rate in patients of group A treated with interferon alpha (9/17, 52.9%) was higher than that in patients treated with combinational lamivudine and matrine (5/16, 31.3%, P<0.05), which was higher than that in the patients treated with lamivudine alone (1/17, 5.9%, P<0.01), and the Knodell histological activity index score in patients treated with lamivudine (7.2+/-0.8, P<0.05) was lower than that in patients treated with interferon alpha (8.2+/-1.3, P<0.05), and the best efficacy was found in receiving combinational therapy (6.9+/-0.7, P<0.01); Lamivudine or lamivudine in combination with matrine significantly inhibited the intrahepatic inflammatory activities, but had no effect on the existing fibrosis in group B patients. CONCLUSION: Long term nucleotide analogues treatment may delay the progress of fibrosis in hepatitis B-induced hepatic failure survivals, and the administration of matrine in time may further enhance the anti-fibrotic effect of nucleotide analogues.